f5 Therapeutics develops targeted protein degraders using its NExMod™ platform to identify novel neosubstrates for the treatment of oncology, immuno-oncology, and autoimmune diseases. By focusing on protein degradation rather than traditional cytotoxic agents, the company aims to provide effective therapies for patients with limited treatment options.
Funding
Funding not disclosed
Founders
Product
Problem
Many disease-causing proteins are not effectively targeted by traditional therapeutics. Conventional drugs often struggle to bind to these proteins or inhibit their function, leaving patients with limited treatment options.
Solution
f5 Therapeutics is developing targeted protein degraders using its NExMod™ (Neosubstrate Expression Modulators) platform to identify novel neosubstrates. This approach focuses on degrading disease-causing proteins rather than simply inhibiting them. By leveraging molecular glues, f5 Therapeutics aims to create effective therapies for oncology, immuno-oncology, and autoimmune diseases, including degrader antibody conjugates.
Target Audience
The primary target audience includes patients with cancer, autoimmune diseases, and other conditions with limited treatment options, as well as pharmaceutical companies interested in partnering for degrader antibody conjugate development.
Features
- NExMod™ platform for identifying novel neosubstrates
- Focus on targeted protein degradation via molecular glues
- Development of monotherapy assets and degrader antibody conjugates
- Discovery of novel "warheads" for protein degradation
- Pipeline of assets targeting a diverse set of novel targets